Arrowhead Pharmaceuticals, Inc.
Compositions and methods for inhibiting gene expression of Hif2alpha

Abstract:

RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2.alpha. (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2.alpha. RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2.alpha. RNAi triggers to tumor cells in vivo provides for inhibition of Hif2.alpha. gene expression and treatment of cancer.